Keywords: yamanouchi, develop, searle, celecoxib, japan, pharmaceutical, signed
Yamanouchi To Develop Searle's Celecoxib In Japan
Article | 29 April 1996
Searle and Yamanouchi Pharmaceutical have signed an agreement whereby Yamanouchi will codevelop and comarket Searle's new oral anti-inflammatory agent, celecoxib, ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
